Back to top

Image: Bigstock

Top Ranked Momentum Stocks to Buy for March 21st

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st:

Bio-Rad Laboratories, Inc. (BIO - Free Report) : This manufacturer of products and solutions for life science research has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.

Bio-Rad Laboratories’ shares gained 13.3% over the last one month against the S&P 500’s rise of 1.8%. The company possesses a Momentum Score of B.

DENTSPLY SIRONA Inc. (XRAY - Free Report) : This dental and oral health products manufacturer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.5% over the last 60 days.

DENTSPLY SIRONA’s shares gained 17.4% over the last one month. The company possesses a Momentum Score of A.

Lantheus Holdings, Inc. (LNTH - Free Report) : This diagnostic medical imaging agents and products manufacturer has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 17.2% over the last 60 days.

Lantheus’ shares gained 16.4% over the last one month. The company possesses a Momentum Score of A.

Masimo Corporation (MASI - Free Report) : This medical technology company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.

Masimo’s shares gained 3.7% over the last one month. The company possesses a Momentum Score of A.

See the full list of top ranked stocks here.

Learn more about the Momentum score and how it is calculated here.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?

From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.

This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.

See Stocks Today >>



More from Zacks Zacks #1 Rank Additions

You May Like